
bms.com
Aug 23, 2025, 10:15
FDA Granted Breakthrough Therapy Designation for Treating NSCLC – BMS
Bristol Myers Squibb (BMS) shared a post on X:
“The FDA U.S. has granted Breakthrough Therapy Designation to our investigational EGFRxHER3 bispecific ADC for previously treated EGFR-mutant NSCLC.
More posts featuring Bristol Myers Squibb on OncoDaily
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Aug 23, 2025, 10:15
Aug 23, 2025, 09:57
Aug 23, 2025, 09:34
Aug 23, 2025, 08:21
Aug 23, 2025, 07:24